Found: 5
Select item for more details and to access through your institution.
Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines.
- Published in:
- NPJ Vaccines, 2020, v. 5, n. 1, p. 1, doi. 10.1038/s41541-020-0165-x
- By:
- Publication type:
- Article
Genetic depletion of the RNA helicase DDX3 leads to impaired elongation of translating ribosomes triggering co-translational quality control of newly synthesized polypeptides.
- Published in:
- Nucleic Acids Research, 2021, v. 49, n. 16, p. 9459, doi. 10.1093/nar/gkab667
- By:
- Publication type:
- Article
Lack of detectable HPV18 antibodies in 14% of quadrivalent vaccinees in a longitudinal cohort study.
- Published in:
- NPJ Vaccines, 2024, v. 9, n. 1, p. 1, doi. 10.1038/s41541-024-00941-w
- By:
- Publication type:
- Article
A safe and potentiated multi-type HPV L2-E7 nanoparticle vaccine with combined prophylactic and therapeutic activity.
- Published in:
- NPJ Vaccines, 2024, v. 9, n. 1, p. 1, doi. 10.1038/s41541-024-00914-z
- By:
- Publication type:
- Article
Scientific approaches toward improving cervical cancer elimination strategies.
- Published in:
- International Journal of Cancer, 2024, v. 154, n. 9, p. 1537, doi. 10.1002/ijc.34839
- By:
- Publication type:
- Article